Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04017546 · ClinicalTrials.gov registry record · Phase 1
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
A Phase 1 study of AML and MDS, sponsored by Cyclacel Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04017546: Completed Phase 1 study of AML and MDS, sponsored by Cyclacel Pharmaceuticals.
NCT04017546 is a Phase 1 study of AML and MDS that has completed, run by Cyclacel Pharmaceuticals. The registered enrollment target is 14 participants, below the 133-participant average among 29 other AML trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04017546, a Phase 1 study of AML and MDS, has completed, sponsored by Cyclacel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory AML or MDS
Primary Outcome
Number of patients who experience dose-limiting toxicity (DLT)
Interventions
- DRUG Venetoclax
- DRUG CYC065
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-08-02 |
| Est. Completion | 2023-04-05 |
| Phase | Phase 1 |
What the finished NCT04017546 record still lists
NCT04017546 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 29 other AML trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with AML appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT04017546 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04017546 about?
NCT04017546 is a clinical study titled "CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS". A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory AML or MDS
What is the current status of trial NCT04017546?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2019-08-02. Estimated completion is 2023-04-05.
What conditions does trial NCT04017546 study?
This clinical trial studies the following conditions: AML, MDS.
What interventions are being tested in trial NCT04017546?
The interventions under investigation include: Venetoclax (DRUG), CYC065 (DRUG).
Who is sponsoring clinical trial NCT04017546?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04017546 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AML
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04017546's enrollment target sits among peer trials
14 28th of 29 higher than 2 of 29 other AML trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other AML trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
CC-486 and Venetoclax for Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy